EvaLuAtion On the cHaracteristics of the True/False lUmen and Its Prognostic Value for cOronary CTO Patients Just Before Stent Implantation

Inclusion Criteria: * 18 to 80 years old; * be diagnosed with CTO; * CTO located in an epicardial coronary artery with a reference diameter of ≥ 2.5mm; * comply with all the evaluations and follow-up protocols. Exclusion Criteria: * suffered from acute myocardial infarction within the previous 3 months; * rheumatic valvular disease; * severe arrhythmia; * lesions unsuitable for PCI; * severely abnormal hematopoietic systems, such as platelet counts \<100\*10\^9/L or \> 700\*10\^9/L and white blood cell counts \< 3\*10\^9/L; * with active bleeding or bleeding tendencies(active ulcers, short-term ischemic stroke, history of hemorrhagic stroke, intracranial space occupying lesions, recent craniocerebral trauma, and other bleeding or bleeding tendency); * severe coexisting conditions, including severe renal function dysfunction \[Glomerular filtration rate less than 60ml/min • 1.73 m2), severe hepatic dysfunction \[glutamic-pyruvic transaminase (ALT) or glutamic-oxal acetic transaminase (ALT) elevated more than three times that of the upper limit of the normal reference\], severe heart failure (NYHA classification III-IV), acute infectious diseases and immune disorders; tumors; surgery within 3 months; * a life expectancy less than 12 months; * pregnancy or planning to become pregnant; * history of allergy or adverse reactions to aspirin, clopidogrel, ticagrelor, stains, contrast material, anticoagulant, or stents; * cannot tolerate dual antiplatelet treatment; * unable to communicate due to cognitive impairment, auditory, or visual impairment; * participating in another trial for medication or an apparatus and in which the main endpoint has not been reached, or plan to participate in a clinical trial within 12 months of the intervention.